{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:56:39Z","timestamp":1794333399903,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hoya Corporation","award":["H-ZGAB"],"award-info":[{"award-number":["H-ZGAB"]}]},{"DOI":"10.13039\/501100004377","name":"Hong Kong Polytechnic University","doi-asserted-by":"publisher","award":["848K, RUQT"],"award-info":[{"award-number":["848K, RUQT"]}],"id":[{"id":"10.13039\/501100004377","id-type":"DOI","asserted-by":"publisher"}]},{"name":"InnoHK initiative and the Hong Kong Special Administrative Region Government."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study evaluated the long-term myopia control effect and safety in children wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. Participants who completed the 2-year RCT were followed for a total of 6\u00a0years; their cycloplegic refractions and axial length were measured. Group 1 (n\u2009=\u200936) wore DIMS spectacles for 6\u00a0years; Group 2 (n\u2009=\u200914) wore DIMS lens for the first 3.5\u00a0years and SV spectacles afterwards; Group 3 (n\u2009=\u200922) wore SV spectacles in the first 2\u00a0years and switched to DIMS; Group 4 (n\u2009=\u200918) wore SV spectacles in the first 2\u00a0years, switched to DIMS for 1.5\u00a0years and then SV spectacles again. Group 1 showed no significant differences in myopia progression (\u2212 0.52\u2009\u00b1\u20090.66 vs. \u2212 0.40\u2009\u00b1\u20090.72D) and axial elongation (0.32\u2009\u00b1\u20090.26 vs. 0.28\u2009\u00b1\u20090.28\u00a0mm, both\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05) between the first and the later 3\u00a0years. In the last 2.5\u00a0years, DIMS lens groups (Groups 1 and 3) had less myopia progression and axial elongation than the single vision groups (Groups 2 and 4). There was no evidence of rebound after stopping the treatment. Post-wear visual functions in all groups were within norms. The results supported that DIMS lenses provided sustained myopia control without adverse effects over the 6-year study period.\n                  <\/jats:p>\n                  <jats:p>Trial registration: clinicaltrials.gov; NCT02206217.<\/jats:p>","DOI":"10.1038\/s41598-023-32700-7","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T07:12:19Z","timestamp":1680592339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6\u00a0years"],"prefix":"10.1038","volume":"13","author":[{"given":"Carly Siu Yin","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Chun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Yan Yin","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vlasak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Ho","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"issue":"5","key":"32700_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden, B. A. et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123(5), 1036\u20131042 (2016).","journal-title":"Ophthalmology"},{"key":"32700_CR2","unstructured":"IAPB: WHO - Global initiative for the elimination of blindness. https:\/\/www.iapb.org\/resources\/who-global-initiative-for-the-elimination-of-blindness\/ (cited on 5th May 2020)"},{"key":"32700_CR3","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","volume":"60","author":"DI Flitcroft","year":"2019","unstructured":"Flitcroft, D. I. et al. IMI\u2014Defining and classifying myopia: A proposed set of standards for clinical and epidemiologic studies. Invest. Ophthalmol. Vis. Sci. 60, M20-30 (2019).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR4","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","volume":"134","author":"JW Tideman","year":"2016","unstructured":"Tideman, J. W. et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA. Ophthalmol. 134, 1355\u20131363 (2016).","journal-title":"JAMA. Ophthalmol."},{"key":"32700_CR5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ophtha.2015.03.022","volume":"122","author":"Y Tang","year":"2015","unstructured":"Tang, Y. et al. Prevalence and causes of visual impairment in a Chinese adult population: The Taizhou Eye Study. Ophthalmology 122, 1480\u20131488 (2015).","journal-title":"Ophthalmology"},{"key":"32700_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/519276a","volume":"519","author":"E Dolgin","year":"2015","unstructured":"Dolgin, E. The myopia boom. Nature 519, 276\u2013278 (2015).","journal-title":"Nature"},{"key":"32700_CR7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","volume":"379","author":"IG Morgan","year":"2012","unstructured":"Morgan, I. G., Ohno-Matsui, K. & Saw, S. M. Myopia. The Lancet 379, 1739\u20131748 (2012).","journal-title":"The Lancet"},{"key":"32700_CR8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua, W. H. et al. Atropine for the treatment of childhood myopia. Ophthalmology 113, 2285\u20132291 (2006).","journal-title":"Ophthalmology"},{"key":"32700_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia, A., Lu, Q. S. & Tan, D. (ATOM-2) five-year clinical trial on Atropine for the treatment of Myopia 2: Myopia control with atropine 0.01% eyedrops. Ophthalmology 123, 391\u2013399 (2016).","journal-title":"Ophthalmology"},{"key":"32700_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jop.2015.0043","volume":"31","author":"TY Clark","year":"2015","unstructured":"Clark, T. Y. & Clark, R. A. Atropine 0.01% Eyedrops significantly reduce the progression of childhood myopia. J. Ocul. Pharmacol. Ther. 31, 541\u2013545 (2015).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"32700_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam, J. C. et al. Low-concentration atropine for myopia progression (LAMP) study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology 126, 113\u2013124 (2019).","journal-title":"Ophthalmology"},{"key":"32700_CR12","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1167\/iovs.12-10565","volume":"53","author":"P Cho","year":"2012","unstructured":"Cho, P. & Cheung, S. W. Retardation of myopia in orthokeratology (ROMIO) study: A 2-year randomized clinical trial. Invest. Ophthalmol. Vis. Sci. 53, 7077\u20137085 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR13","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1167\/iovs.11-8453","volume":"53","author":"T Hiraoka","year":"2012","unstructured":"Hiraoka, T. et al. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: A 5-year follow-up study. Invest. Ophthalmol. Vis. Sci. 53, 3913\u20133919 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR14","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1167\/iovs.11-8005","volume":"53","author":"J Santodomingo-Rubido","year":"2012","unstructured":"Santodomingo-Rubido, J. et al. Myopia control with orthokeratology contact lenses in Spain: Refractive and biometric changes. Invest. Ophthalmol. Vis. Sci. 53, 5060\u20135065 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","volume":"104","author":"CSY Lam","year":"2020","unstructured":"Lam, C. S. Y. et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: A 2-year randomised clinical trial. Br. J. Ophthalmol. 104, 363\u2013368 (2020).","journal-title":"Br. J. Ophthalmol."},{"issue":"5","key":"32700_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaophthalmol.2022.0401","volume":"140","author":"J Bao","year":"2022","unstructured":"Bao, J. et al. Spectacle lenses with aspherical lenslets for myopia control versus single-vision spectacle lenses: A randomized clinical trial. JAMA. Ophthalmol. 140(5), 472\u2013478 (2022).","journal-title":"JAMA. Ophthalmol."},{"key":"32700_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/bjophthalmol-2013-303914","volume":"98","author":"CS Lam","year":"2014","unstructured":"Lam, C. S. et al. Defocus incorporated soft contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: A 2-year randomized clinical trial. Br. J. Ophthalmol. 98, 40\u201345 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"32700_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/OPX.0000000000001410","volume":"96","author":"P Chamberlain","year":"2019","unstructured":"Chamberlain, P. et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom. Vis. Sci. 96, 556\u2013567 (2019).","journal-title":"Optom. Vis. Sci."},{"key":"32700_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2020.10834","volume":"24","author":"JJ Walline","year":"2020","unstructured":"Walline, J. J. et al. BLINK Study Group. Effect of high add power, medium add power, or single-vision contact lenses on Myopia progression in children: The BLINK randomized clinical trial. JAMA 24, 571\u2013580 (2020).","journal-title":"JAMA"},{"key":"32700_CR20","first-page":"1110","volume":"106","author":"CS Lam","year":"2022","unstructured":"Lam, C. S. et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: Results of a 3-year follow-up study. Br. J. Ophthalmol. 106, 1110\u20131114 (2022).","journal-title":"Br. J. Ophthalmol."},{"key":"32700_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamaophthalmol.2013.7623","volume":"132","author":"D Cheng","year":"2014","unstructured":"Cheng, D. et al. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: Three-year results of a randomized clinical trial. JAMA. Ophthalmol. 132, 258\u2013264 (2014).","journal-title":"JAMA. Ophthalmol."},{"key":"32700_CR22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/OPX.0000000000001873","volume":"99","author":"P Chamberlain","year":"2022","unstructured":"Chamberlain, P. et al. Long-term effect of dual-focus contact lenses on myopia progression in children: A 6-year multicenter clinical trial. Optom. Vis. Sci. 99, 204\u2013212 (2022).","journal-title":"Optom. Vis. Sci."},{"key":"32700_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/OPX.0000000000001977","volume":"100","author":"MA Bullimore","year":"2023","unstructured":"Bullimore, M. A. & Brennan, N. A. Efficacy in Myopia control: Does race matter?. Optom. Vis. Sci. 100, 5\u20138 (2023).","journal-title":"Optom. Vis. Sci."},{"key":"32700_CR24","doi-asserted-by":"publisher","first-page":"M132","DOI":"10.1167\/iovs.18-25955","volume":"60","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn, J. S. et al. IMI\u2014Clinical Myopia control trials and instrumentation report. Invest. Ophthalmol. Vis. Sci. 60, M132\u2013M160 (2019).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319568","author":"A Ducloux","year":"2021","unstructured":"Ducloux, A. et al. Progression of myopia in teenagers and adults: A nationwide longitudinal study of a prevalent cohort. Br. J. Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319568 (2021).","journal-title":"Br. J. Ophthalmol."},{"key":"32700_CR26","first-page":"3629","volume":"55","author":"P Sankaridurg","year":"2014","unstructured":"Sankaridurg, P. et al. An annual rate of myopic progression model for Asian children. Invest. Ophthalmol. Vis. Sci. 55, 3629 (2014).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/OPX.0b013e3182357f79","volume":"89","author":"L Donovan","year":"2012","unstructured":"Donovan, L. et al. Myopia progression rates in urban children wearing single-vision spectacles. Optom. Vis. Sci. 89, 27\u201332 (2012).","journal-title":"Optom. Vis. Sci."},{"key":"32700_CR28","first-page":"E-abstract 2100","volume":"98","author":"P Chamberlain","year":"2021","unstructured":"Chamberlain, P. et al. Myopia progression on cessation of dual-focus contact lens wear: MiSight 1 day 7-year findings. Optom. Vis. Sci. 98, E-abstract 210049 (2021).","journal-title":"Optom. Vis. Sci."},{"key":"32700_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1167\/iovs.11-7769","volume":"53","author":"DA Berntsen","year":"2012","unstructured":"Berntsen, D. A. et al. A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation. Invest Ophthalmol. Vis. Sci. 53, 640\u2013649 (2012).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"32700_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","volume":"116","author":"L Tong","year":"2009","unstructured":"Tong, L. et al. Atropine for the treatment of childhood myopia: Effect on myopia progression after cessation of atropine. Ophthalmology 116, 572\u2013579 (2009).","journal-title":"Ophthalmology"},{"key":"32700_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clae.2016.12.002","volume":"40","author":"P Cho","year":"2017","unstructured":"Cho, P. & Cheung, S. W. Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont. Lens. Anterior. Eye. 40, 82\u201387 (2017).","journal-title":"Cont. Lens. Anterior. Eye."},{"key":"32700_CR32","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1167\/iovs.03-1151","volume":"45","author":"DS Fan","year":"2004","unstructured":"Fan, D. S. et al. Prevalence, incidence, and progression of myopia of school children in Hong Kong. Invest. Ophthalmol. Vis. Sci. 45, 1071\u20131075 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR33","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1136\/bjophthalmol-2020-316234","volume":"106","author":"JR Polling","year":"2022","unstructured":"Polling, J. R., Klaver, C. & Tideman, J. W. Myopia progression from wearing first glasses to adult age: The DREAM Study. Br. J. Ophthalmol. 106, 820\u2013824 (2022).","journal-title":"Br. J. Ophthalmol."},{"key":"32700_CR34","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1167\/iovs.06-0562","volume":"48","author":"DO Mutti","year":"2007","unstructured":"Mutti, D. O. et al. Refractive error, axial length, and relative peripheral refractive error before and after the onset of myopia. Invest. Ophthalmol. Vis. Sci. 48, 2510\u20132519 (2007).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"32700_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2188\/jea.JE20140258","volume":"26","author":"WJ Zhou","year":"2016","unstructured":"Zhou, W. J. et al. Five-year progression of refractive errors and incidence of Myopia in school-aged children in western China. J Epidemiol. 26, 386\u2013395 (2016).","journal-title":"J Epidemiol."},{"key":"32700_CR36","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.preteyeres.2020.100923","volume":"83","author":"NA Brennan","year":"2021","unstructured":"Brennan, N. A. et al. Efficacy in myopia control. Prog. Retin. Eye. Res. 83, 100923 (2021).","journal-title":"Prog. Retin. Eye. Res."},{"key":"32700_CR37","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3390\/jcm11092294","volume":"11","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Myopia control effect is influenced by baseline relative peripheral refraction in children wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. J. Clin. Med. 11, 2294 (2022).","journal-title":"J. Clin. Med."},{"key":"32700_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1167\/iovs.61.5.53","volume":"61","author":"HY Zhang","year":"2020","unstructured":"Zhang, H. Y. et al. Defocus incorporated multiple segments spectacle lenses changed the relative peripheral refraction: A 2-year randomized clinical trial. Invest. Ophthalmol. Vis. Sci. 61, 53 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32700-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:39:19Z","timestamp":1702168759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32700-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32700"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32700-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5475"}}